Advertisement

Topics

PubMed Journals Articles About "Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC)" RSS

19:15 EDT 20th June 2019 | BioPortfolio

Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) articles that have been published worldwide.

More Information about "Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC)" on BioPortfolio

We have published hundreds of Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) news stories on BioPortfolio along with dozens of Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) Clinical Trials and PubMed Articles about Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) Companies in our database. You can also find out about relevant Infusion Of Toripalimab Via Neck Artery Versus Vein For Immunotherapy Of Head/Neck Cancers (HNC) Drugs and Medications on this site too.

Showing "Infusion Toripalimab Neck Artery Versus Vein Immunotherapy Head" PubMed Articles 1–25 of 11,000+

Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.

In a span of a few years, the surprising early successes of programmed cell death 1 (PD-1) inhibitors across a vast range of tumor types have transformed our understanding of cancer immunogenicity and provided proof of principle that T cells, if manipulated, can mediate meaningful tumor regression. In head and neck cancer, only a minority of patients respond to PD-1 therapy, but these small outcomes have fueled the enthusiasm for the next generation of immunotherapy-adoptive cell therapy-which employs recen...


The impact of time after radiation treatment on dysphagia in patients with head and neck cancer enrolled in a swallowing therapy program.

Swallowing dysfunction after radiotherapy (RT) for head and neck cancer can be devastating. A randomized control trial compared swallow exercises versus exercise plus neuromuscular electrical stimulation therapy and found no overall difference in outcomes.

The value of immunotherapy in head and neck cancer.

Head and neck squamous cell carcinomas (HNSCC) previously had limited treatment options once patients had progressed on systemic chemotherapy. With recent advances, immunotherapy now plays an important role in the treatment of advanced disease with improved outcomes as compared to cytotoxic chemotherapy. Areas covered: This article reviews the effects of the immune system and how it influences the development and response to HNSCC therapy. We additionally provide a summary of immunotherapy treatments availa...


Quality of life in patients after reconstruction with the supraclavicular artery island flap (SCAIF) versus the radial free forearm flap (RFFF).

Gold-standard for defect reconstruction in the head and neck region is the radial free forearm flap (RFFF). The supraclavicular artery island flap (SCAIF) gained popularity due to its versatility. Our objective was to compare functional advantages between both modalities.

Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: A comparative analysis.

Cisplatin-based chemoradiotherapy is standard of care for locally advanced squamous cell carcinoma of the head and neck. This systemic review compared efficacy and safety of weekly vs triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck.

American Society of Anesthesiologists Class as Predictor for Perioperative Morbidity in Head and Neck Free Flaps.

To evaluate outcomes of free flaps in low- versus high-risk American Society of Anesthesiologists (ASA) classes utilizing a standardized perioperative clinical pathway.

Reporting of Cosmesis in Head and Neck Reconstruction: A Systematic Review.

To identify the method and rate at which cosmesis is reported after reconstruction from head and neck surgery among adults.

Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.

Recommendations for perioperative therapy in head and neck cancer are not explicit and recurrence occurs frequently. Circulating tumor DNA is an emerging cancer biomarker, but has not been extensively explored for detection of recurrence in head and neck cancer.

Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.

Checkpoint inhibitors (CPI) are revolutionizing the treatment of advanced cancers including recurrent and or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.

Radiation therapy for squamous cell cancer of the head and neck with unknown primary (head and neck CUP) has been associated with significant levels of swallowing toxicity. We examined the effect of changes in mucosal dose on development of laryngeal strictures and percutaneous endoscopic gastrostomy (PEG) dependence.

Toripalimab: First Global Approval.

Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers. In December 2018, based on positive efficacy results of a phase 2 trial and safety data from several clinical studies, toripalimab received conditional approval in China for the treatment of unresectable or meta...

Assessment of Gender Differences in Perceptions of Work-Life Integration Among Head and Neck Surgeons.

The factors that contribute to gender discrepancies among attending head and neck surgeons have yet to be fully characterized.

Outcomes and cost implications of microvascular reconstructions of the head and neck.

Critical review of current head and neck reconstructive practices as related to free flap donor sites and their impact on clinical outcomes and cost.

Antegrade hepatic artery and portal vein perfusion versus portal vein perfusion alone in live donor liver transplantation: a randomized trial.

Traditionally, deceased donor liver grafts receive dual perfusion through the portal vein and the hepatic artery(HA) either in-situ or on the back-table. Hepatic artery perfusion is avoided in live donor liver grafts for fear of damage to the intima and consequent risk of hepatic artery thrombosis(HAT). However, biliary vasculature is predominantly derived from the HA. We hypothesized that antegrade perfusion of the HA in addition to the portal vein on the back table could reduce the incidence of post-opera...

Assessing functional outcomes in head and neck surgical oncology.

A reliable method of measuring functional outcomes is essential to inform treatment decisions in head and neck cancer.

Desmoid tumors of the head and neck: Two decades in a single tertiary care unit and review of the literature.

Desmoid tumors (DTs) of the head and neck have typically been classified as extra-abdominal, although the anatomic challenges of the head and neck warrant consideration of these DTs as a special entity. We present a review of DTs and describe our series of five patients with DTs of the head and neck treated within 2 decades. Altogether, 53 patients with DTs treated surgically at a tertiary care center over a 20-year period were retrospectively reviewed. Outcomes of the treatment of DTs of the head and neck ...

Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.

Triweekly high-dose cisplatin (100 mg/m ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m with alternative weekly 40 mg/m and weekly

Prophylactic human papilloma virus vaccination in head and neck: indications and future perspectives.

To gain the evidence-based knowledge concerning the efficacy of HPV vaccination for oropharyngeal sites and to highlight the trials and strategies for vaccine administration in HPV-dependent head and neck diseases.

Development of a Methodology for Simulating Complex Head Impacts With the Advanced Combat Helmet.

Blunt impact assessment of the Advanced Combat Helmet (ACH) is currently based on the linear head response. The current study presents a methodology for testing the ACH under complex loading that generates linear and rotational head motion. Experiments were performed on a guided, free-fall drop tower using an instrumented National Operating Committee for Standards on Athletic Equipment (NOCSAE) head attached to a Hybrid III (HIII) or EuroSID-2 (ES-2) dummy neck and carriage. Rear and lateral impacts occurre...

When Have We Done Enough? Provider-Patient Discord in Terminal Head and Neck Cancer.

Using the Motion of the Head-Neck as a Joystick for Orientation Control.

Head-neck interfaces have the potential to command and control orientation tasks when the hand-wrist is not available for use as a joystick. We pose the question in this paper - How well can the head-neck be used to perform orientation tasks when compared to the hand-wrist? Anatomically, the motion of the head-neck is similar to that of the hand-wrist. We hypothesize that the head-neck motion can be as effective as the motion of the hand-wrist to control orientation tasks. A study was designed to characteri...

Outcomes of dental and craniofacial osseointegrated implantation in head and neck cancer patients.

Treatment of head and neck cancer may result in disfiguring and debilitating anatomical changes. Osseointegrated implants may be used in these patients to facilitate attachment of implant-retained dentures or cosmetic prostheses.

Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy.

Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment.

In Vivo PSMA Expression in Head and Neck Paragangliomas on 68Ga PSMA 11 PET/CT.

Head and neck paragangliomas are rare and often asymptomatic tumors and mostly present as painless masses. We describe Ga PSMA 11 PET/CT and Ga DOTANOC PET/CT findings of a 40 year old man with triple head and neck paragangliomas with emphasis on exploring the possible theranostic options.

Impact of head and neck cancer on partner's sociability.

"Sociability" is defined as the range of experiences linking the subject to others. This is the first study to focus specifically on the impact of head and neck cancer on the sociability of patients' partners.


Advertisement
Quick Search
Advertisement
Advertisement